2022, Number 4
<< Back Next >>
Cir Card Mex 2022; 7 (4)
Incidence of intracardiac thrombi in times of Covid 19
Martínez-Pérez AM, Echeverry-Gutiérrez MA, Estrada-Castañeda HI, Martínez HMR, Álvarez-Moreno CC, Cuevas-Álvarez R
Language: English
References: 22
Page: 65-69
PDF size: 398.29 Kb.
ABSTRACT
Objective. To find the relationship in patients with a history
of COVID 19, with the increased presentation of
intracardiac thrombi.
Material. This is an observational,
cross-sectional, retrospective study, with review of
cases in electronic and physical files, starting in March
2020, and ending in May 2022, including patients with
intracardiac thrombi during the COVID 19 pandemic,
in our institution. Descriptive data were reported as percentages,
ranges, and means.
Results. A total of 12 patients,
with age range between 20 to 46 years, mean of
34.5 years, of which 6 women (50%) and 6 men (50%). As
background, 6 patients presented symptomatic COVID
19 and positive test (50%), none vaccinated prior to the
onset of symptoms. Chronic kidney disease was identified
in 9 patients (75%), 8 with a Mahurkar catheter;
7 required removal of the Mahurkar catheter during
surgery. Of the remaining 25% (n=3), 1 female patient
presented HELLP syndrome, episodes of deep vein
thrombosis and pulmonary thromboembolism; another
female presented thrombi attached to the dual-chamber
pacemaker requiring removal, without bacterial growth
in the culture, and another only with a history of diabetes
mellitus. All presented intracardiac thrombus were
at the level of the right atrium.
Conclusions. There is a
strong relationship between the history of COVID 19
and the presentation of intracardiac thrombi, as well
as an increased incidence in patients with risk factors,
mainly chronic kidney disease present in 75% of cases
with the presence of a Mahurkar catheter.
REFERENCES
Tan W, Zhao X, Ma X, et al. A Novel Coronavirus Genome Identified in a Clusterof Pneumonia Cases - Wuhan, China 2019-2020. China CDC Wkly. 2020;2(4):61-62.
Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193-292. doi: 10.1016/S0065-3527(06)66005-3.
Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group forCovid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N EnglJ Med. 2020;382(18):1708-1720. doi: 10.1056/NEJMoa2002032.
Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality inhospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiology.2020;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitisin COVID-19. Lancet. 2020;395(10234):1417-1418. doi: 10.1016/S0140-
6736(20)30937-5.6. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injuryand thrombosis in the pathogenesis of severe COVID 19 infection a report of fivecases. Transl. Res. 2020; 220 :1-13. doi: 10.1016/j.trsl.2020.04.007.
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysison the receptor ACE2 expression reveals the potential risk of different humanorgans vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192. doi:10.1007/s11684-020-0754-0.
Subramaniam S, Scharrer I. Procoagulant activity during viral infections. FrontBiosci (Landmark Ed). 2018 Jan 1;23(6):1060-1081. doi: 10.2741/4633.
Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS.Pulmonary and cardiac pathology in African American patients with COVID-19:an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. doi:
10.1016/S2213-2600(20)30243-5.10. Kinney EL, Wright RJ. Efficacy of treatment of patients with echocardiographicallydetected right-sided heart thrombi: a meta-analysis. Am Heart J.1989;118(3):569-73. doi: 10.1016/0002-8703(89)90274-3.
The European Cooperative Study on the clinical significance of right heart thrombi.European Working Group on Echocardiography. Eur Heart J. 1989;10(12):1046-59. doi: 10.1093/oxfordjournals.eurheartj.a059427.
Torbicki A, Galié N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPERStudy Group. Right heart thrombi in pulmonary embolism: results from theInternational Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol.2003;41(12):2245-51. doi: 10.1016/s0735-1097(03)00479-0.
Crowell RH, Adams GS, Koilpillai CJ, McNutt EJ, Montague TJ. In vivo rightheart thrombus. Precursor of life-threatening pulmonary embolism. Chest. 1988Dec;94(6):1236-9. doi: 10.1378/chest.94.6.1236.
Thompson CA, Skelton TN. Thromboembolism in the right side of the heart.South Med J. 1999;92(8):826-30. doi: 10.1097/00007611-199908000-00018.
Ferrari E, Benhamou M, Berthier F, Baudouy M. Mobile thrombi of the right heartin pulmonary embolism: delayed disappearance after thrombolytic treatment.Chest. 2005 Mar;127(3):1051-3. doi: 10.1378/chest.127.3.1051.
Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest.2002;121(3):806-14. doi: 10.1378/chest.121.3.806.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.
Koć M, Kostrubiec M, Elikowski W, et al; RiHTER Investigators. Outcome ofpatients with right heart thrombi: The Right Heart Thrombi European Registry.Eur Respir J. 2016;47(3):869-75. doi: 10.1183/13993003.00819-2015.
Anthi A, Konstantonis D, Theodorakopoulou M, et al. A Severe COVID-19 CaseComplicated by Right Atrium Thrombus. Am J Case Rep. 2020;21:e926915. doi:10.12659/AJCR.926915.
Tran MH, Wilcox T, Tran PN. Catheter-related right atrial thrombosis. J Vasc Access.2020;21(3):300-307. doi: 10.1177/1129729819873851.
Stavroulopoulos A, Aresti V, Zounis C. Right atrial thrombi complicating haemodialysiscatheters. A meta-analysis of reported cases and a proposal of a managementalgorithm. Nephrol Dial Transplant. 2012;27(7):2936-44. doi: 10.1093/ndt/gfr739.
Bigdelian H, Sedighi M, Sabri MR, et al. Case Report: Acute Intracardiac Thrombosisin Children with Coronavirus Disease 2019 (COVID-19). Front Pediatr.2021;9:656720. doi: 10.3389/fped.2021.656720.
Full text